Roche Discount Fails to Win Breast-Cancer Drug U.K. BackingBy
NICE says NHS can't afford Roche's Kadcyla in final decision
Patients taking Kadcyla don't have to stop taking it
Roche Holding AG failed to win the endorsement of the U.K.’s health-cost regulator for its breast-cancer medicine Kadcyla, capping two years of haggling over the cost of the treatment.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.